Skip to content
Review Open access

Bridging genotype and clinical phenotype: a multi-evidence framework for KCNMA1 variant interpretation

Nov 2026 · Frontiers in Pharmacology · 0 citations · 43 references

Abstract

Patient-associated KCNMA1 variants are associated with a range of neurological disorders and considerable phenotypic and genetic heterogeneity. The rare prevalence of the disorder, paucity of inherited variants or individuals sharing the same variant, lack of diagnostic standardization, and incomplete understanding of the relationship between the KCNMA1 gene product and disease phenotype, have complicated the interpretations of KCNMA1 variant pathogenicity. In this study, we developed a KCNMA1 patient registry to characterize the variants, clinical phenotypes, and natural history reported by participants (or their caretakers). Registry data was combined with additional unpublished cases and literature reports, and systematic KCNMA1 variant curation was performed to determine the proportion of pathogenic, benign, and uncertain variants. A total of 49 surveys were analyzed from 33 KCNMA1 Registry participants, including longitudinal data from 45% of participants. Registry variants were combined with additional published KCNMA1 variants and unsolicited direct email communications, representing 172 cases worldwide. Variants were classified using a standardized scheme adapted from the American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) guidelines with KCNMA1 -specific criteria. Registry participants most frequently reported neurodevelopmental abnormalities (88%), movement disorders (82%), and seizures (64%), with early age of onset (median = 0.8, interquartile range = 0.5–2.75 years). Longitudinal analysis revealed that most participants reported no significant change in symptoms over time (73%). Across all sources, 107 unique KCNMA1 variants were interpreted, including 16 novel variants. In total, 45% of KCNMA1 variants were classified as (likely) pathogenic (P = 10, LP = 38) and 16% as (likely) benign (LB = 12, B = 5), while 39% (n = 42) did not have sufficient evidence to be classified beyond uncertain significance (VUS). This study establishes a standardized instrument for KCNMA1 patient data collection and a consistent multi-evidence variant interpretation framework, including population frequency, segregation and allelic data, computational predictions, and functional studies. This standardized KCNMA1 variant interpretation will reduce diagnostic uncertainty and form the foundation of improved genotype–phenotype correlation in this rare disorder.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.